Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SI-B001 and SI-B003 in Advanced Head and Neck Squamous Cell Carcinoma
NCT05668858Phase 2Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Feb 2023
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of izalontamab and SI-B003 in head and neck squamous cell carcinoma (HNSCC), sponsored by Biokin Pharmaceutical. Primary endpoints: Recommended Phase II Dose at 24 months, Objective Response Rate at 24 months and 2 more. Started Feb 2023; status: active, not recruiting.
02
Drugs
izalontamabSI-B003
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05668858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05668858.